vat-cit-pab-monomethyl dolastatin 10

Vat-Cit-PAB-Monomethyl Dolastatin 10 is an ADC linker-conjugated drug designed to deliver potent antitumor activity. It achieves this through Monomethyl Dolastatin 10, a potent tubulin inhibitor, connected via the Vat-Cit-PAB ADC linker.

Fmoc-Val-Cit-PAB-MMAE 由 ADC 接头 (Fmoc-Val-Cit-PAB) 和强效微管蛋白抑制剂 (MMAE) 组成。 它是一种用于 ADC 的药物-接头偶联物。

MC-Val-Cit-PAB 是一种组织蛋白酶可裂解的 ADC 接头，用于制备抗体-药物偶联物。

Fmoc-Val-Cit-PAB 是一种可降解的抗体-药物偶联的连接剂。

Boc-Val-Cit-PAB-PNP 是一种可切割的 ADC 接头，用于合成抗体-药物偶联物。

Boc-Val-Cit-PAB 是一种可切割的 ADC 接头，用于抗体-药物偶联物的合成。

Val-cit-PAB-OH 是可降解ADC 连接剂。

Mc-Val-Cit-PAB-Cl 是一种可切割的 ADC 接头，可用于偶联 MMAE 和抗体以形成抗体-MC-vc-MMAE。

Val-Cit-PAB-MMAE 是 ADC 的药物-接头偶联物。它包含 ADC 接头（肽 Val-Cit-PAB）和有效的微管蛋白抑制剂 MMAE。

OPSS-Val-Cit-PAB-PNP is a cleavable linker employed in ADC (antibody-drug conjugates) synthesis [1].

The chemical compound Mal-Phe-C4-Val-Cit-PAB-DMEA is a cleavable antibody-drug conjugate (ADC) linker that incorporates a Maleimide group. It is commonly employed in the synthesis of ADCs.

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker employed in the synthesis of ADCs[1].

Mal-PEG4-Val-Cit-PAB-OH, a cleavable 4-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Sq-Cit-PAB-Dolastatin10 is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Dolastatin10 (a tubulin polymerization inhibitor) connected through the MC-Sq-Cit-PAB ADC linker.

MAL-di-EG-Val-Cit-PAB-MMAF refers to a chemical compound that comprises the linker (MAL-di-EG-Val-Cit-PAB) and the potent blocker of tubulin polymerization (MMAF, Monomethyl auristatin F)[1].

MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate designed for antibody-drug conjugates (ADC), featuring the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected through the MC-Val-Cit-PAB ADC linker. This configuration endows it with significant antitumor activity.

Endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable four-unit polyethylene glycol (PEG) linker, specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-Val-Cit-PAB-PNP is a cleavable 4-unit polyethylene glycol (PEG) linker employed in the synthesis of antibody-drug conjugates (ADCs)[1].

DBCO-(PEG2-Val-Cit-PAB)2 is a dual-cleavable linker used in antibody-drug conjugates (ADCs).

Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable 2-unit polyethylene glycol (PEG) based ADC linker utilized in the construction of antibody-drug conjugates (ADCs)[1].

OPSS-Val-Cit-PAB-OH is an ADC linker utilized for the synthesis of antibody-drug conjugates (ADCs) [1].

Mal-Phe-C4-Val-Cit-PAB is a cleavable antibody-drug conjugate (ADC) linker featuring a Maleimide functional group. It is employed in the synthesis of ADCs.

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker comprising the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the SuO-Val-Cit-PAB peptide.

Mal-PEG8-Val-Cit-PAB-MMAE is a cleavable 8-unit PEG ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate employed in antibody-drug conjugates (ADCs) that exhibits robust antitumor efficacy. This conjugate utilizes the ADC linker, MC-Val-Cit-PAB, to link to the potent antitumor agent dimethylDNA31. Notably, dimethylDNA31 also demonstrates significant bactericidal activity against both persister and stationary-phase Staphylococcus aureus.

Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker employed for synthesizing antibody-drug conjugates (ADCs)[1]. It also serves as a PEG-based PROTAC linker for the synthesis of PROTACs[2].

Azido-PEG3-Val-Cit-PAB-OH is a cleavable three-unit polyethylene glycol antibody-drug conjugate (ADC) linker utilized in ADC synthesis [1].

MC-Sq-Cit-PAB-Gefitinib is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Gefitinib—an EGFR tyrosine kinase inhibitor—connected through the MC-Sq-Cit-PAB ADC linker.

Azido-PEG4-Val-Cit-PAB-OH is a 4-unit PEG ADC linker and a PEG-based PROTAC linker. It is employed for the synthesis of antibody-drug conjugates (ADCs)[1] and PROTACs[2].

Mal-PEG4-Val-Cit-PAB, a cleavable ADC linker incorporating a Maleimide moiety, finds application in the construction of antibody-drug conjugates (ADCs)[1].

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound featuring Auristatin E, a potent cytotoxic tubulin modifier, connected through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mal-amido-PEG2-Val-Cit-PAB-OH is a bi-functional polyethylene glycol (PEG) linker, comprised of two PEG units, that can be cleaved. It is specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

MAL-di-EG-Val-Cit-PAB-MMAE comprises the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, which are essential components of antibody-drug conjugates (ADCs).

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

MC-Val-Cit-PAB-Indibulin is an antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), featuring the orally active tubulin assembly inhibitor, Indibulin, connected through the MC-Val-Cit-PAB ADC linker. This compound exhibits potent antitumor activity.

Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linker conjugate designed for antibody-drug conjugation (ADC), utilizing the antitumor antibiotic Duocarmycin TM. It is connected through the linker Fmoc-Val-Cit-PAB.

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

mDPR(Boc)-Val-Cit-PAB is a cleavable linker employed in antibody-drug conjugates (ADCs) [1]. This chemical compound serves as a reliable linker in the formation of ADCs, which are biopharmaceuticals that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs for targeted cancer therapy [1].

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

MC-Val-Cit-PAB-clindamycin is an antibody-drug conjugate (ADC) linker that combines the potent antitumor properties of clindamycin, a protein synthesis inhibitor, with the ADC linker MC-Val-Cit-PAB, to enhance its ability to target and kill cancer cells effectively.

SC-Val-Cit-PAB is a cleavable ADC linker for antibody-drug conjugates (ADCs).

mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.

MC-Val-Cit-PAB-vinblastine is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), featuring vinblastine (a microtubule protein inhibitor) connected through the MC-Val-Cit-PAB ADC linker.

MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for antibody-drug conjugates (ADC) that exhibits potent antitumor activity. This compound utilizes Retapamulin, a ribosome inhibitor, connected through the ADC linker MC-Val-Cit-PAB.